Population pharmacokinetics of anidulafungin in critically ill patients

S. Luque, W. Hope, N. Campillo, R. Muñoz-Bermúdez, L. Sorli, J. Barceló-Vidal, E. González-Colominas, F. Alvarez-Lerma, J. R. Masclans, M. Montero, J. P. Horcajada, S. Graua

Producció científica: Contribució a revistaArticleRecerca

14 Cites (Scopus)

Resum

Copyright © 2019 American Society for Microbiology. All Rights Reserved. A two-compartment pharmacokinetic (PK) population model of anidulafungin was fitted to PK data from 23 critically ill patients (age, 65 years [range, 28 to 81 years]; total body weight [TBW], 75 kg [range, 54 to 168 kg]). TBW was associated with clearance and incorporated into a final population PK model. Simulations suggested that patients with higher TBWs had less-extensive MIC coverage. Dosage escalation may be warranted in patients with high TBWs to ensure optimal drug exposures for treatment of Candida albicans and Candida glabrata infections.
Idioma originalAnglès
Número d’articlee00378-19
RevistaAntimicrobial Agents and Chemotherapy
Volum63
Número7
DOIs
Estat de la publicacióPublicada - de jul. 2019

Fingerprint

Navegar pels temes de recerca de 'Population pharmacokinetics of anidulafungin in critically ill patients'. Junts formen un fingerprint únic.

Com citar-ho